Related Experiment Video
Updated: May 25, 2026

Corneal Sensitivity Testing Procedure for Ophthalmologic and Optometric Patients
Published on: August 2, 2024
Clinical Features of Corneal Adverse Events Associated With Trastuzumab Botidotin: Payload-Driven Epitheliopathy and
Yongyi Zhang1, Gege Tang1, Jingjie Zhang1
1From the Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Purpose:
HER2-targeted antibody-drug conjugates (ADCs) demonstrate significant efficacy in HER2-mutated or HER2-positive tumors but may cause ocular adverse events (AEs), particularly corneal epitheliopathy and blurred vision. This study aimed to characterize the clinical features of trastuzumab botidotin (a HER2-targeted ADC)-related corneal AEs.
Design:
Retrospective case series.
Subjects:
Eight adult patients (15 eyes) with HER2-mutated or HER2-positive solid tumors treated with trastuzumab botidotin.
Methods:
Assessments included best-corrected visual acuity, Ocular Surface Disease Index, Schirmer's test, tear break-up time, tear meniscus height, and corneal fluorescein staining. In vivo confocal microscopy (IVCM) was performed to evaluate cellular structures and confirm lesion characteristics.
Main Outcome Measures:
Corneal AEs associated with trastuzumab botidotin and their clinical features.
Results:
Corneal AEs occurred in all eight patients. The mean time to visual impairment onset was 37.25 ± 5.90 days after trastuzumab botidotin initiation, with symptom severity peaking at 82.75 ± 14.26 days. Ocular Surface Disease Index scores increased from 5.73 ± 2.67 at baseline to 65.10 ± 13.26 at peak severity. Trastuzumab botidotin caused dry eye in all patients (n = 8), resulting in reduced Schirmer's test results (from 8.94 ± 1.66 mm to 4.20 ± 1.58 mm), shortened tear break-up time (from 9.63 ± 1.21 seconds to 3.37 ± 1.61 seconds), and decreased tear meniscus height (from 0.23 ± 0.04 mm to 0.14 ± 0.02 mm). Slit-lamp microscopy and fluorescein staining revealed that trastuzumab botidotin induced distinct corneal epitheliopathy, characterized by pseudomicrocysts, punctate epitheliopathy, diffuse punctate epitheliopathy, and vortex keratopathy. IVCM correlated these findings, showing cyst-like hyperreflective structures in the superficial epithelium, grape-like hyperreflective clusters in wing cells and basal cells, and associated cellular disorganization. IVCM demonstrated neurotoxic damage, characterized by thinning of subbasal nerves, decreased nerve density, and focal discontinuities in the subbasal nerve plexus.
Conclusions:
Trastuzumab botidotin was associated with visual impairment, corneal epitheliopathy, and nerve damage. Close collaboration between ophthalmologists and oncologists is crucial for early detection of corneal AEs related to ADC therapy, thereby improving clinical outcomes and patient quality of life.
Insights
Trastuzumab botidotin, a HER2-targeted antibody-drug conjugate, caused ocular adverse events including corneal epitheliopathy and blurred vision in all patients studied. Early detection and collaboration are key for managing these side effects.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- HER2-targeted antibody-drug conjugates (ADCs) are effective cancer therapies.
- Ocular adverse events (AEs), such as corneal epitheliopathy and blurred vision, are known side effects of ADCs.
- Trastuzumab botidotin is a HER2-targeted ADC used for HER2-mutated or HER2-positive tumors.
Purpose of the Study:
- To characterize the clinical features of corneal AEs associated with trastuzumab botidotin.
- To evaluate the impact of trastuzumab botidotin on ocular surface parameters and corneal cellular structures.
Main Methods:
- Retrospective case series of eight adult patients treated with trastuzumab botidotin.
- Ophthalmic assessments included visual acuity, Ocular Surface Disease Index (OSDI), Schirmer's test, tear break-up time (TBUT), tear meniscus height (TMH), and corneal fluorescein staining (CFS).
- In vivo confocal microscopy (IVCM) was used to examine corneal cellular structures and nerve damage.
Main Results:
- All patients experienced corneal AEs, with visual impairment onset around 37 days and peak severity around 83 days.
- Trastuzumab botidotin induced dry eye, significantly reducing tear production, TBUT, and TMH.
- Corneal epitheliopathy manifested as pseudomicrocysts and vortex keratopathy, confirmed by IVCM showing cellular disorganization and neurotoxic damage to subbasal nerves.
Conclusions:
- Trastuzumab botidotin is associated with significant visual impairment, corneal epitheliopathy, and nerve damage.
- Prompt identification of these corneal AEs is crucial for managing patients on ADC therapy.
- Collaboration between ophthalmologists and oncologists can improve patient outcomes and quality of life.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Drug Toxicity: Dose-Dependent Reactions
Cytotoxic Edema: Pathophysiology
Drug toxicity: Idiosyncratic Reactions
Drug Toxicity: Overview
Hypersensitivity Reactions: Cytolytic Reactions
